Research News

Ticagrelor is no better than aspirin at preventing cardiovascular events after acute stroke or TIA, study finds

BMJ 2016; 353 doi: (Published 12 May 2016) Cite this as: BMJ 2016;353:i2654
  1. Susan Mayor
  1. London

Ticagrelor, a direct acting antiplatelet agent, is no more effective than aspirin at preventing recurrent stroke, myocardial infarction, or death in patients who have an ischaemic stroke or transient ischaemic attack (TIA), a randomised trial has shown.1

The risk of a further ischaemic event is high in the first 90 days after a stroke or TIA, so aspirin is commonly used to reduce thrombotic risk. But a risk …

View Full Text

Log in

Log in through your institution


* For online subscription